Latest Information Update: 24 May 2001
$50 / €47 *
At a glance
- Originator Genentech
- Class Antineoplastics
- Mechanism of Action Somatotropin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 May 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 18 Apr 1997 No-Development-Reported for Cancer in USA (Unknown route)
- 21 Jun 1995 This profile is new.